Loading
Latest filing published 01 Oct 2026 for Fortress Biotech, Inc., €1,909.
Not enough history yet: 1 closed purchase, at least 2 are needed.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
David Jin discloses dealings in 3 companies, chiefly Fortress Biotech, Inc., Avenue Therapeutics, Inc. and Mustang Bio, Inc. Over a trading history stretching from 26 October 2022 to 1 October 2026, the count stands at 15 filings.
On the market, this insider has only ever bought: 4 purchases, €34k in total. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. The rest of the record consists of 11 share grants.
A typical purchase (the median) is worth €3,087. Of 4 purchases, 3 formed part of a group of insiders buying within 30 days of each other. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase.
The latest filing, published on 1 October 2026, reports a share grant of €1,909 in Fortress Biotech, Inc. The most recent open-market purchase was published on 30 December 2025, 298 days ago. Typically, a trade is published a median of 2 days after it takes place. For comparison, the SEC allows two business days to file a Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
15 of 15 declarations